Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


09.10.2017

3 Am J Hematol
3 Ann Hematol
4 Blood
2 Br J Haematol
1 Cancer
1 Cancer Res
1 Eur J Haematol
1 Exp Hematol
4 Int J Hematol
2 Leuk Lymphoma
13 Leuk Res
1 Leukemia
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. IZZI V, Lakkala J, Devarajan R, Savolainen ER, et al
    Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24925.
    PubMed     Text format    

  2. LAZAREVIC VL, Labopin M, Wu D, Yakoub-Agha I, et al
    Relatively favourable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24928.
    PubMed     Text format     Abstract available

  3. EL FAKIH R, Jabbour E, Ravandi F, Hassanein M, et al
    Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24926.
    PubMed     Text format     Abstract available


    Ann Hematol

  4. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Text format     Abstract available

  5. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Text format     Abstract available

  6. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.
    PubMed     Text format    


    Blood

  7. BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
    First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
    PubMed     Text format     Abstract available

  8. TASIAN SK, Loh ML, Hunger SP
    Philadelphia chromosome-like acute lymphoblastic leukemia.
    Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
    PubMed     Text format     Abstract available

  9. WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
    PubMed     Text format     Abstract available

  10. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017;130:1620-1627.
    PubMed     Text format     Abstract available


    Br J Haematol

  11. ALVAREZ-LARRAN A, Senin A, Fernandez-Rodriguez C, Pereira A, et al
    Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
    Br J Haematol. 2017;178:764-771.
    PubMed     Text format     Abstract available

  12. ZHANG X, Yang L, Liu X, Nie Z, et al
    Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
    Br J Haematol. 2017;178:728-738.
    PubMed     Text format     Abstract available


    Cancer

  13. SHEN C, Zhao B, Liu L, Shih YT, et al
    Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31050.
    PubMed     Text format     Abstract available


    Cancer Res

  14. DE GRANDIS M, Bardin F, Fauriat C, Zemmour C, et al
    JAM-C identifies Src family kinase-activated leukemia-initiating cells and predicts poor prognosis in acute myeloid leukemia.
    Cancer Res. 2017 Sep 28. pii: canres.1223.2017.
    PubMed     Text format     Abstract available


    Eur J Haematol

  15. TULSTRUP M, Frandsen TL, Abrahamsson J, Lund B, et al
    Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: a NOPHO randomized controlled trial.
    Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12979.
    PubMed     Text format     Abstract available


    Exp Hematol

  16. HASSAN C, Afshinnekoo E, Li S, Wu S, et al
    Genetic and epigenetic heterogeneity and the impact on cancer relapse.
    Exp Hematol. 2017;54:26-30.
    PubMed     Text format     Abstract available


    Int J Hematol

  17. HUA Y, Wang C, Jiang H, Wang Y, et al
    Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
    Int J Hematol. 2017;106:248-257.
    PubMed     Text format     Abstract available

  18. HAYASHI Y, Harada Y, Huang G, Harada H, et al
    Myeloid neoplasms with germ line RUNX1 mutation.
    Int J Hematol. 2017;106:183-188.
    PubMed     Text format     Abstract available

  19. CHEAH JJC, Hahn CN, Hiwase DK, Scott HS, et al
    Myeloid neoplasms with germline DDX41 mutation.
    Int J Hematol. 2017;106:163-174.
    PubMed     Text format     Abstract available

  20. FEURSTEIN S, Godley LA
    Germline ETV6 mutations and predisposition to hematological malignancies.
    Int J Hematol. 2017;106:189-195.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  21. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed     Text format    

  22. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    Leuk Res

  23. VALENT P, Hadzijusufovic E, Hoermann G, Fureder W, et al
    Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.
    Leuk Res. 2017;59:47-54.
    PubMed     Text format     Abstract available

  24. LEISCH M, Weiss L, Lindlbauer N, Jungbauer C, et al
    Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
    Leuk Res. 2017;59:12-19.
    PubMed     Text format     Abstract available

  25. POPP HD, Naumann N, Brendel S, Henzler T, et al
    Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
    Leuk Res. 2017;57:112-118.
    PubMed     Text format     Abstract available

  26. STRUPP C, Nachtkamp K, Hildebrandt B, Giagounidis A, et al
    New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
    Leuk Res. 2017;57:78-84.
    PubMed     Text format     Abstract available

  27. SADRAS T, Kok CH, Perugini M, Ramshaw HS, et al
    miR-155 as a potential target of IL-3 signaling in primary AML cells.
    Leuk Res. 2017;57:57-59.
    PubMed     Text format     Abstract available

  28. HILAL T, Slone S, Peterson S, Bodine C, et al
    Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy.
    Leuk Res. 2017;57:37-44.
    PubMed     Text format     Abstract available

  29. HERSHENFELD SA, Maki K, Rothfels L, Murray CS, et al
    Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.
    Leuk Res. 2017;59:93-96.
    PubMed     Text format     Abstract available

  30. MASAROVA L, Bose P, Daver N, Pemmaraju N, et al
    Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Leuk Res. 2017;59:110-116.
    PubMed     Text format     Abstract available

  31. AZUMA K, Umezu T, Imanishi S, Asano M, et al
    Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.
    Leuk Res. 2017;62:23-28.
    PubMed     Text format     Abstract available

  32. ZHOU K, Song Y, Zhang Y, Wei X, et al
    Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
    Leuk Res. 2017;62:29-33.
    PubMed     Text format     Abstract available

  33. HUANG Y, Zou Y, Lin L, Ma X, et al
    Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells.
    Leuk Res. 2017;62:34-39.
    PubMed     Text format     Abstract available

  34. AHMED T, Koch AL, Isom S, Klepin HD, et al
    Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.
    Leuk Res. 2017;62:51-55.
    PubMed     Text format     Abstract available

  35. HENKENIUS K, Greene BH, Barckhausen C, Hartmann R, et al
    Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia.
    Leuk Res. 2017;62:56-63.
    PubMed     Text format     Abstract available


    Leukemia

  36. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
    RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    PLoS One

  37. GORDIIENKO I, Shlapatska L, Kholodniuk V, Sklyarenko L, et al
    The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
    PLoS One. 2017;12:e0185940.
    PubMed     Text format     Abstract available

  38. LATHAM S, Hughes E, Budgen B, Mechinaud F, et al
    Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.
    PLoS One. 2017;12:e0185556.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: